The 11 linked references in paper S. Zyryanov K., K. Zatolochina E., V. Cheltsov V., С. Зырянов К., К. Затолочина Э., В. Чельцов В. (2017) “Возможна ли взаимозаменяемость лекарственных препаратов для ингаляционного применения? // Could inhalational drugs be interchangeable?” / spz:neicon:pulmonology:y:2017:i:4:p:529-536

  1. Daley-Yates P.T., Parkins D.A. Establishing bioequivalence for inhaled drug; weighing the evidence.Expert Opin. Drug Deliv.2011; 8 (10): 1297–1308. DOI: 10.1517/17425247. 2011.592827.
  2. Price D., Haughney J., Sims E. et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J. Asthma Allergy. 2011; 4: 37–47. DOI: 10.2147/JAA.S17709.
  3. Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.J. Aerosol. Med.2005; 18 (3): 273–282. DOI: 10.1089/jam. 2005.18. 273.
  4. Ninbovorl J., Sawatdee S., Srichana T. Factor affecting the stability and performance of ipratropium bromide; fenoterol hydrobromide pressurized-metered dose inhalers. AAPS PharmSci'Tech.2013; 14 (4): 1294–1302. DOI: 10.1208/ s12249-013-0024-4.
  5. Nimmo C.J., Chen D.N., Martinusen S.M. et al. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices.Ann. Pharmacother.1993; 27 (7–8): 922–927. DOI: 10.1177/106002809302700721.
  6. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2agonist particle size. Am. J. Respir. Crit. Care Med. 2005, 172 (12): 1497–1504. DOI: 10.1164/rccm.200410-1414OC.
  7. Laube B.L., Janssens H.M., de Jongh F.H et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J.2011; 37 (6): 1308–1331. DOI: 10.1183/09031936.00166410.
  8. Архипов В.В., Архипова Д.Е., Лазарева Н.Б. Новые ингаляционные устройства для терапии хронической обструктивной болезни легких. Пульмонология. 2016; 26 (3): 352–356. DOI: 10.18093/0869-0189-2016-26-3352-356. (the paper at Socionet)
  9. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007; 6 (1): 67–74. DOI: 10.1038/nrd2153.
  10. 7; 156: 744–751. 19. Clearie K.I., Williamson P.A., Vaidyanathan S. et al. Systemic bioavailability of hydrofluoroalkane formulation of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br. J. Clin. Pharmacol.2010; 69 (6): 637–644. DOI: 10.1111/j.1365-2125.2010.03655.x.
  11. Bateman E.D., Tashkin D., Siafakas N. et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med.2010; 104 (10): 1460–1472. DOI: 10.1016/j.rmed.2010.06.004.